Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Orexo

13.44 SEK+0.30 %11.9, 13.31
Less than 1K followers

ORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+0.30 %
-9.80 %
-31.36 %
-45.14 %
-55.35 %
-45.81 %
-24.75 %
-59.57 %
-85.06 %

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Read more
Market cap
499.39M SEK
Turnover
87.24K SEK
Revenue
26M
EBIT %
-1,356.54 %
P/E
0.73
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22.10
2026

Interim report Q3'26

4.2
2027

Annual report '26

Press release10.09.2026, 08.00

BARDA Supports Contract Modification extending the initial Development stage for the OX390 project to end of 2027

Orexo
Press release01.09.2026, 21.00

Fredrik Järrsten resigns as CFO of Orexo AB

Orexo
Press release31.08.2026, 16.55

DNB Carnegie Access: Orexo: Highlights from DNB Carnegie’s Micro Cap Day

Orexo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release31.08.2026, 09.15

DNB Carnegie Access: Orexo: Reaches a non-binding settlement with DOJ

Orexo
Regulatory press release31.08.2026, 08.00

Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice

Orexo
Press release17.07.2026, 06.55

DNB Carnegie Access: Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review

Orexo
Regulatory press release16.07.2026, 07.00

Orexo Q2 2026 Interim Report

Orexo
Press release10.07.2026, 11.00

Invitation to presentation of Orexo´s Q2 2026 Interim Report

Orexo
Press release09.06.2026, 08.00

Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships

Orexo
Press release19.05.2026, 11.38

DNB Carnegie Access: Orexo: Promising early-stage data

Orexo
Press release19.05.2026, 08.00

Orexo announces positive outcome from an in-vivo study of OX390

Orexo
Regulatory press release07.05.2026, 17.00

Report from Orexo AB’s annual general meeting May 7 2026

Orexo
Press release29.04.2026, 08.40

DNB Carnegie Access: Orexo: Better visibility, few near-term catalysts – Q1 review

Orexo
Regulatory press release28.04.2026, 07.00

Orexo Q1 2026 Interim Report

Orexo
Press release21.04.2026, 10.00

Invitation to presentation of Orexo´s Q1 2026 Interim Report

Orexo
Regulatory press release31.03.2026, 17.30

Number of shares and votes in Orexo

Orexo
Press release30.03.2026, 12.00

Notice of Annual General Meeting of Orexo

Orexo
Regulatory press release27.03.2026, 10.00

Orexo publishes Annual Report for 2025

Orexo
Press release24.03.2026, 19.53

DNB Carnegie Access: Orexo: Key takeaways from R&D Day

Orexo
Press release24.03.2026, 07.30

Orexo R&D Day - Building global leadership in amorphous drug delivery

Orexo